Evaluating the Health Impact of Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease: Insights from a Contemporary, Prospective Population-Based Study of Hong Kong
Description: Objectives:
Metabolic-dysfunction associated fatty liver disease (MAFLD) is a new nomenclature introduced in 2020, and prospective outcome studies evaluating its health impact are still limited. We aim to investigate an updated incidence and fibrosis progression rate of MAFLD, as well as the risks of developing extra-hepatic outcomes, as compared to non-alcoholic fatty liver disease (NAFLD).
Hypotheses
We hypothesize that the incidence, rate of fibrosis progression and risks of development of extra-hepatic outcomes, in particular incident type 2 diabetes (T2D), will be significantly higher in MAFLD compared to that of NAFLD.
Design:
A contemporary, prospective population-based cohort study.
Subjects:
Participants of the New Hong Kong Cardiovascular Risk Factor Prevalence Study (NCRISPS) who are recruited by systematic replicating sampling of representative replicates of living quarters in Hong Kong at baseline.
Instruments:
Comprehensive metabolic profiling including oral glucose tolerance test (OGTT) for evaluation of glycaemic status, and hepatic assessments using vibration-controlled transient elastography (VCTE) for liver steatosis and fibrosis
Interventions: N/A
Main outcome measures:
Updated local incidence and fibrosis progression rate of MAFLD and its different subtypes, risk and risk factors of fibrosis progression and development of extra-hepatic outcomes including glycaemic progression, incident T2D, cardiovascular and chronic kidney diseases.
Data analysis:
Multivariable Cox regression analyses to estimate the hazards ratios for the primary and secondary outcomes, employing the generalized estimating equation approach, with adjustments for baseline and time-varying covariates.
Expected results:
MAFLD as a multi-system disease with higher incidence and risks of both liver fibrosis and incident extra-hepatic outcomes compared to NAFLD.
Funder: Health and Medical Research Fund
Amount: HKD 1,462,000
Funding type: grant
Funder scheme: HMRF - Health and Health Services (including HHSRF)
Start date: 2022-01-01
Investigator: Paul Chi-ho LEE (lead)
Institutions: University of Hong Kong, Department of Medicine, The University of Hong Kong
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 0
Funder award ID: 21222691
OpenAlex ID: G5822535538
